WO2005046666A8 - Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz - Google Patents

Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz

Info

Publication number
WO2005046666A8
WO2005046666A8 PCT/EP2004/011692 EP2004011692W WO2005046666A8 WO 2005046666 A8 WO2005046666 A8 WO 2005046666A8 EP 2004011692 W EP2004011692 W EP 2004011692W WO 2005046666 A8 WO2005046666 A8 WO 2005046666A8
Authority
WO
WIPO (PCT)
Prior art keywords
incontinence
pharmaceutical composition
mixed
treating stress
stress incontinence
Prior art date
Application number
PCT/EP2004/011692
Other languages
English (en)
French (fr)
Other versions
WO2005046666A1 (de
Inventor
Martin Michel
Marion Wienrich
Ursula Ebinger
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Martin Michel
Marion Wienrich
Ursula Ebinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Martin Michel, Marion Wienrich, Ursula Ebinger filed Critical Boehringer Ingelheim Int
Priority to JP2006537123A priority Critical patent/JP2007509868A/ja
Priority to CA002544048A priority patent/CA2544048A1/en
Priority to EP04790529A priority patent/EP1703903A1/de
Publication of WO2005046666A1 publication Critical patent/WO2005046666A1/de
Publication of WO2005046666A8 publication Critical patent/WO2005046666A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Diese Erfindung beschreibt die Verwendung von beta-3-Adrenozeptor-Agonisten zur Behandlung von Harnblasenfunktionsstörungen, insbesondere der Stressinkontinenz und/oder der Mischinkontinenz.
PCT/EP2004/011692 2003-10-31 2004-10-16 Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz WO2005046666A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006537123A JP2007509868A (ja) 2003-10-31 2004-10-16 緊張性尿失禁及び／又は混合型尿失禁治療用医薬組成物
CA002544048A CA2544048A1 (en) 2003-10-31 2004-10-16 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
EP04790529A EP1703903A1 (de) 2003-10-31 2004-10-16 Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10351271.3 2003-10-31
DE10351271A DE10351271A1 (de) 2003-10-31 2003-10-31 Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz

Publications (2)

Publication Number Publication Date
WO2005046666A1 WO2005046666A1 (de) 2005-05-26
WO2005046666A8 true WO2005046666A8 (de) 2005-08-04

Family

ID=34530073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011692 WO2005046666A1 (de) 2003-10-31 2004-10-16 Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz

Country Status (6)

Country Link
US (2) US20060004105A1 (de)
EP (1) EP1703903A1 (de)
JP (1) JP2007509868A (de)
CA (1) CA2544048A1 (de)
DE (1) DE10351271A1 (de)
WO (1) WO2005046666A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DE60229404D1 (de) * 2001-09-13 2008-11-27 Kissei Pharmaceutical Kristalle eines hydroxynorephedrinderivats
JP3815496B2 (ja) * 2002-11-07 2006-08-30 アステラス製薬株式会社 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Also Published As

Publication number Publication date
DE10351271A1 (de) 2005-06-02
JP2007509868A (ja) 2007-04-19
US20060004105A1 (en) 2006-01-05
CA2544048A1 (en) 2005-05-26
EP1703903A1 (de) 2006-09-27
US20070129435A1 (en) 2007-06-07
WO2005046666A1 (de) 2005-05-26

Similar Documents

Publication Publication Date Title
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2004047838A3 (de) Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika
EP1859793A4 (de) Neue kombinierte anwendung einer sulfonamid-verbindung
WO2006044825A3 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
EP2248524A3 (de) Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
WO2004080391A3 (en) Novel antibacterial agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2005 UNDER (71) FOR "BOEHRINGER INGELHEIM INTERNATIONAL GMBH" REPLACE THE EXISTING TEXT BY "APPLICANT (FOR ALL DESIGNATED STATES EXCEPT DE, US)"

WWE Wipo information: entry into national phase

Ref document number: 2004790529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2544048

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006537123

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004790529

Country of ref document: EP